IMAPAC | Cell & Gene Therapy World Asia 2026

#CGTAsia2026: driving breakthroughs in research, clinical applications, and manufacturing, while addressing Asia’s unique challenges.

As the region emerges as a global leader in regenerative medicine, Cell & Gene Therapy World Asia 2026 (#CGTAsia2026) returns as Asia’s most anticipated CGT knowledge-sharing conference for the 9th year! Designed to connect and empower stakeholders from the cell and gene therapy ecosystem, the event provides an unparalleled platform to explore the latest advancements in cell therapies, gene therapies, and CAR-T technologies.

Register today to secure your ticket.

Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.

Chethan A J is currently working as Assistant Director Quality Assurance and Regulatory Affairs at Center for Ocular Regeneration (CORE), LV Prasad Eye Institute, Hyderabad, India specializing in Quality Management System, Risk Management and Indian Regulatory Affairs. With over 13 years of experience in Cell and Gene therapy field, Chethan has involved and led the team in various aspects of CMC such as manufacturing, Quality Assurance and Regulatory Affairs. Under his leadership the CORE GMP manufacturing facility could achieve to get manufacturing and test license in form CT-11 for 5 unique cell therapy based products and Clinical trial license for Phase I trial for 2 unique cell therapy products in for CT-06 from Indian FDA, CDSCO. He is expert in deriving Quality Management System in Cell therapy products which meets the compliance to the required cGMP standards. He holds a master degree in Medical Biochemistry from Manipal University, MBA in Total Quality Management, Diploma in GMP, Six Sigma Green belt and certified Internal Auditor for ISO 9001:2015 QMS. He is an active member of Society of Quality Assurance (SQA) and Indian Society for Clinical Research (ISCR). Outside of work Chethan enjoys hiking, photography, sports & fitness.

Ryuichi Morishita, M.D., Ph.D., graduated Osaka University Medical School in 1987, and received Ph. D. from Osaka University in 1991. After following postdoctoral Fellow at Stanford University School of Medicine, he served as an Assistant Professor, Department of Geriatric Medicine, Osaka University Medical School from 1994 to 1998. Then, from 1998 to 2003, he was Associate Professor, Division of Gene Therapy Science, Osaka University Medical School. Then, he became Professor & Chairman of Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University Medical School from 2003 to present.

Dr. Horak brings more than 20 years of experience in the global pharmaceutical industry, predominantly focused on oncology drug development, and is a board-certified medical oncologist. Prior to funding Tikva Allocell, Dr. Horak was Head of Global R&D and Chief Scientific at Tessa Therapeutics, a mid-stage cell therapy company in Singapore. For eight years, he was Chief Medical Officer and Chief Scientific Officer at Symphogen, a clinical-stage antibody company, and President of R&D at Enzon Pharmaceuticals, Inc. Dr. Horak has also held a number of senior research leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI), National Institutes of Health in US. During his career, Dr. Horak has advanced multiple oncology treatments into the clinic, and has successfully led a number of FDA new drug applications.

Biography - A leader with 20+ years of experience in aseptic manufacturing and quality excellence, inspiring innovation and continuous improvement in the pharmaceutical industry.

Chimeric Therapeutics CEO Dr Rebecca McQualter joined the Company in May 2024, bringing senior experience from a range of big pharma roles. Dr McQualter holds a Doctor of Philosophy in Cell Therapy and Regenerative Medicine from Monash University. Dr McQualter has an extensive commercial career with exposure to many aspects of international pharmaceutical operations. This included as the Head of Strategic Access at Novartis Australia, where Dr McQualter developed new commercial partnerships, built external networks spanning policy makers, research institutes and NGOs, and engaged with federal and state government, trade associations and other stakeholders to implement policy and process improvements. Other previous roles include Country Medical Head for Bioverativ ANZ, a $5 billion Biogen spinout focusing on rare diseases, and leadership roles at Amgen and GSK.

Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.

Register your interest to get access to tickets as soon as they go live.

With more than 50 years of experience, Charles River offers an integrated, flexible, and scalable portfolio of contamination control, manufacturing, and biosafety testing products and services, backed by a global organization of science, testing labs, and a team of scientific and regulatory experts to expedite the development process and to support a safe product release. With over 40,000 tests run annually at the GMP biologics testing facilities; Charles River can provide comprehensive testing services for a wide range of modalities. These include monoclonal antibodies/recombinant proteins, viral vectors, vaccines, and cell therapies.